Simvastatin and Disease Stabilization in Normal Tension Glaucoma: A Cohort Study

Ophthalmology

Volumn 117, Issue 3, 2010, Pages 471-476

  Leung, Dexter Y L ^a   Li, Felix C H ^a   Kwong, Yolanda Y Y ^a   Tham, Clement C Y ^a   Chi, Stanley C C ^a   Lam, Dennis S C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

SIMVASTATIN;

ADULT; AGED; ARTICLE; CHINESE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA THICKNESS; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTRAOCULAR PRESSURE; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NORMAL TENSION GLAUCOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; VISUAL FIELD;

AGED; ANTICHOLESTEREMIC AGENTS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTRAOCULAR PRESSURE; LOW TENSION GLAUCOMA; MALE; PERIMETRY; PROSPECTIVE STUDIES; SIMVASTATIN; TONOMETRY, OCULAR; VISION DISORDERS; VISUAL FIELDS;

EID: 77049083375     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.08.016     Document Type: Article

References (35)

1. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 366 (2005) 1267-1278
2. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006) 549-559
3. Sacks F.M., Pfeffer M.A., Moye L.A., et al., Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
4. Kent D.M. Stroke-an equal opportunity for the initiation of statin therapy. N Engl J Med 355 (2006) 613-615
5. Zacco A., Togo J., Spence K., et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 23 (2003) 11104-11111
6. Vaughan C.J., and Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 30 (1999) 1969-1973
7. Honjo M., Tanihara H., Nishijima K., et al. Statin inhibits leukocyte-endothelial interaction and prevents neuronal death induced by ischemia-reperfusion injury in the rat retina. Arch Ophthalmol 120 (2002) 1707-1713
8. Cimino M., Gelosa P., Gianella A., et al. Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist 13 (2007) 208-213
9. Tan J.S., Mitchell P., Rochtchina E., and Wang J.J. Statin use and the long-term risk of incident cataract: the Blue Mountains Eye Study. Am J Ophthalmol 143 (2007) 687-689
10. Tan J.S., Mitchell P., Rochtchina E., and Wang J.J. Statins and the long-term risk of incident age-related macular degeneration: the Blue Mountains Eye Study. Am J Ophthalmol 143 (2007) 685-687
11. Gordon B., Chang S., Kavanagh M., et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol 112 (1991) 385-391
12. Nagaoka T., Takahashi A., Sato E., et al. Effect of systemic administration of simvastatin on retinal circulation. Arch Ophthalmol 124 (2006) 665-670
13. Rao P.V., Deng P.F., Kumar J., and Epstein D.L. Modulation of aqueous humor outflow facility by the Rho kinase specific inhibitor, Y-27632. Invest Ophthalmol Vis Sci 42 (2001) 1029-1037
14. McGwin Jr. G., McNeal S., Owsley C., et al. Statins and other cholesterol-lowering medications and the presence of glaucoma. Arch Ophthalmol 122 (2004) 822-826
15. De Castro D.K., Punjabi O.S., Bostrom A.G., et al. Effect of statin drugs and aspirin on progression in open-angle glaucoma suspects using confocal scanning laser ophthalmoscopy. Clin Experiment Ophthalmol 35 (2007) 506-513
16. Shields M.B. Normal-tension glaucoma: is it different from primary open-angle glaucoma?. Curr Opin Ophthalmol 19 (2008) 85-88
17. Leung D.Y., Tham C.C., Li F.C., et al. Silent cerebral infarct and visual field progression in newly diagnosed normal-tension glaucoma: a cohort study. Ophthalmology 116 (2009) 1250-1256
18. Collaborative Normal-Tension Glaucoma Study Group. Natural history of normal-tension glaucoma. Ophthalmology 108 (2001) 247-253
19. Anderson D.R., Chauhan B., Johnson C., et al. Criteria for progression of glaucoma in clinical management and in outcome studies. Am J Ophthalmol 130 (2000) 827-829
20. Schulzer M. Errors in the diagnosis of visual field progression in normal-tension glaucoma. Ophthalmology 101 (1994) 1589-1594
21. Aung T., Lim M.C., Chan Y.H., et al. Configuration of the drainage angle, intraocular pressure, and optic disc cupping in subjects with chronic angle-closure glaucoma. Ophthalmology 112 (2005) 28-32
22. Leung D.Y., Lam D.K., Yeung B.Y., and Lam D.S. Comparison between central corneal thickness measurements by ultrasound pachymetry and optical coherence tomography. Clin Experiment Ophthalmol 34 (2006) 751-754
23. Quigley H.A., and Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 38 (1997) 83-91
24. Leske M.C., Heijl A., Hussein M., et al., Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol 121 (2003) 48-56
25. Gordon M.O., Beiser J.A., Brandt J.D., et al., Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 120 (2002) 714-720
26. Kim J.W., and Chen P.P. Central corneal pachymetry and visual field progression in patients with open-angle glaucoma. Ophthalmology 111 (2004) 2126-2132
27. Drance S., Anderson D.R., Schulzer M., and Collaborative Normal-Tension Glaucoma Study Group. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol 131 (2001) 699-708
28. Anderson D.R., Drance S.M., Schulzer M., and Collaborative Normal-Tension Glaucoma Study Group. Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma. Am J Ophthalmol 136 (2003) 820-829
29. Kim C., and Kim T.W. Comparison of risk factors for bilateral and unilateral eye involvement in normal-tension glaucoma. Invest Ophthalmol Vis Sci 50 (2009) 1215-1220
30. Kitazawa Y., Shirai H., and Go F.J. The effect of Ca2(+)-antagonist on visual field in low-tension glaucoma. Graefes Arch Clin Exp Ophthalmol 227 (1989) 408-412
31. Bose S., Piltz J.R., and Breton M.E. Nimodipine, a centrally active calcium antagonist, exerts a beneficial effect on contrast sensitivity in patients with normal-tension glaucoma and in control subjects. Ophthalmology 102 (1995) 1236-1241
32. Constad W.H., Fiore P., Samson C., and Cinotti A.A. Use of an angiotensin converting enzyme inhibitor in ocular hypertension and primary open-angle glaucoma. Am J Ophthalmol 105 (1988) 674-677
33. Hirooka K., Baba T., Fujimura T., and Shiraga F. Prevention of visual field defect progression with angiotensin-converting enzyme inhibitor in eyes with normal-tension glaucoma. Am J Ophthalmol 142 (2006) 523-525
34. Fraunfelder F.W., and Richards A.B. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use. Ophthalmology 115 (2008) 2282-2285
35. Chylack Jr. L.T., Wolfe J.K., Singer D.M., et al., Longitudinal Study of Cataract Study Group. The Lens Opacities Classification System III. Arch Ophthalmol 111 (1993) 831-836